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TO THE EDITOR
Melanoma growth and metastasis depend
on a battle between the cancer’s invasive
properties and the host’s capacity to
counter such attributes. Immunosuppres-
sion is a potent promoter of cancer
progression that not only counters host
control of tumor spread but also prevents
anti-cancer treatments from achieving
their full benefit (Ilkovitch and Lopez,
2008). Because CD11bþGr1þ cells are
most potent at suppressing T-cell function
(Frey, 2006), their exponential prolife-
ration in cancer patients severely limits
the efficacy of immunotherapy (Diaz-
Montero et al., 2009).
We discovered the DC-HIL receptor to
potently inhibit effector T-cell function
following binding to syndecan-4 (SD-4)
on these cells (Chung et al., 2007a,b). In
an accompanying article (Chung et al.,
2014), we showed that melanoma-
bearing (but not tumor-free) mice
harbor an expanded population of DC-
HIL-expressing CD11bþGr1þ cells and
that functional blockade of DC-HIL on
these cells via gene deletion or specific
Ab abrogates their suppressor function,
making DC-HIL a marker for immuno-
suppressive CD11bþGr1þ cells and a
powerful promoter of melanoma
growth.
As CD14þHLA-DRno/low cells are the
human equivalent of mouse CD11bþ
Gr1þ cells (Filipazzi et al., 2007), we
posited that blood CD14þHLA-DRno/low
cells in melanoma patients express
DC-HIL and that such expression makes
them immunosuppressive. Thus, we
examined blood frequencies of CD14þ
HLA-DRno/low cells and their DC-HIL
expression in cases of melanoma with
varying clinical stages (0–IV; n¼ 62), in
dysplastic nevi (in which melanocytes
are abnormal but not malignant (n¼ 12)),
and in healthy donors (n¼ 21; Figure 1a
and Supplementary Table S1 online).
Compared with healthy donors, all cases
of melanoma exhibited elevated blood
CD14þHLA-DRno/low cells (Figure 1b),
consistent with a prior report (Filipazzi
et al., 2007). Whereas blood CD14þ
HLA-DRno/low cells in healthy donors
had little-to-no expression of DC-HIL
(0.1±0.1% DC-HILþ cells among peri-
pheral blood monocyte cells, PBMCs),
all cases of metastatic melanoma (stages
III/IV) displayed high-level DC-HIL
expression on these cells (2.9±0.9%
and 2.6±0.6%, respectively; t-test P¼
0.001 vs. healthy donors; Figure 1c).
Intermediate levels of DC-HIL expres-
sion were seen in blood CD14þHLA-
DRno/low cells of melanoma confined to
skin (stages 0/I–II). Dysplastic nevi
showed lower expression compared
with skin-restricted melanoma, but
higher expression compared with
healthy donors (P¼ 0.01). Thus, blood
levels of DC-HILþCD14þHLA-DRno/low
cells correlated with cancer progression,
particularly in advanced stages. Other
myeloid cells thought to have suppressor
function (CD14þ IL-4Raþ , CD14neg
CD11bþCD15þ , and CD14negIL-4Raþ
CD15þ ) also expressed DC-HIL at a
range of 30–75% (Supplementary
Figure S1 online).
To determine whether melanoma was
the cause of the elevated blood levels,
we followed up a new cohort of 9
patients with stage 0 melanoma and
assayed for % DC-HILþCD14þHLA-
DRno/low cells in their PBMCs (Figure 1d)
at 0, 1, 3, and 6 months after excision of
the melanoma. At the time of resection
(0 month), all subjects except one (sub-
ject M83) exhibited higher levels com-
pared with healthy controls (0.3–12.8%;
Supplementary Table S2 online). Across
the 3-month follow-up, these elevated
levels declined significantly in 8 patients
(Wald test, P¼0.045) to an average of
0.4%, close to that of 6 normal controls
(Supplementary Table S3 online). Inter-
estingly, in the case of one patient
(M71), the % DC-HILþCD14þHLA-
DRno/low cells that declined a month post
resection climbed back to a high level at
3 months, which coincided with the
discovery of a new melanoma in situ
(stage 0), and then fell back after resec-
tion of this second melanoma. We con-
cluded that melanoma is responsible
(directly or indirectly) for acquisition of
DC-HIL expression by CD14þHLA-
DRno/low cells. Because our mouse stu-
dies showed IFN-g and IL-1b to induce
DC-HIL expression by CD11bþGr1þ
cells, we speculate similar mechanisms
for human CD14þHLA-DRno/low cells.
Do CD14þHLA-DRno/low cells from
melanoma patients suppress T-cell
function and is DC-HIL responsible for
that function? CD14þHLA-DRno/low
cells isolated from melanoma patients
(vs. healthy donors) were cocultured with
autologous T cells activated by anti-
CD2/CD3/CD28 antibody (Figure 2a).
CD14þHLA-DRno/low cells from mela-
noma patients inhibited IFN-g production
by autologous T cells dose-dependently
and almost completely, whereas corre-
sponding cells from healthy donors were
weakly immunosuppressive.
Treatment with anti-DC-HIL mAb
(but not control IgG) restored the T-cell
IFN-g response dose-dependently (up to
80%; Figure 2b). Moreover, treatment of
total (unfractionated) PBMCs from mel-
anoma patients with anti-DC-HIL mAb
(but not with control IgG) enhanced the
IFN-g response, and this enhancement
correlated positively with melanoma
staging (Figure 2c) but negatively with
IFN-g levels from IgG-treated PBMCs
(Figure 2d).
Our outcomes indicated that neutra-
lizing DC-HIL’s T cell–suppressiveAccepted article preview online 16 June 2014; published online 17 July 2014
Abbreviations: PBMC, peripheral blood monocyte cell; SD-4, Syndecan-4
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function could be beneficial to mela-
noma patients. Among currently avail-
able treatments for melanoma, the most
closely related to a DC-HIL antagonist is
humanized mAb directed against
CTLA-4 (ipilimumab) or PD-1 (lambro-
lizumab). Both treatments have been
shown to prolong survival of patients
with metastatic melanoma (Hodi et al.,
2010; Hamid et al., 2013), presumably
by blocking the inhibitory functions of
CTLA-4 and PD-1, respectively. How-
ever, their benefits have been limited
by development of autoimmune disease
causing dermatitis, hepatitis, colitis, and
in many cases death (Hodi et al., 2010),
making the search for even better
treatments important.
Our mouse studies showed that, unlike
DC-HIL, the ligands for CTLA-4 (CD80
and CD86) and PD-1 (PD-L1) are not
critically involved in the T-cell suppressor
function of myeloid cells. Moreover,
both CTLA-4 and PD-1 are expressed by
most activated T cells and regulate the
development of autoreactive T cells via
regulatory T-cell function (Gattinoni
et al., 2006). By contrast, SD-4 (the DC-
HIL ligand) is expressed by only a
restricted population of effector T cells,
with no impact on regulatory T-cell
function (Chung et al., 2013). Finally,
CTLA-4 / or PD-1 / mice develop
spontaneous autoimmune diseases (Tivol
et al., 1995; Nishimura et al., 1999) cau-
sing early death, whereas DC-HIL / or
SD-4 / mice survive without obser-
vable autoimmune diseases (unpublished
data). These differences suggest that
strategies neutralizing DC-HIL function
may restore T-cell function in melanoma
patients via mechanisms different from
those of CTLA-4 or PD-1 blockers.
In sum, the positive correlation
between % blood DC-HILþCD14þ
HLA-DRno/low cells and advancing mel-
anoma stage, this parameter’s quick
decline after resection of early
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Figure 1. Positive correlation between DC-HILþCD14þHLA-DRno/low cells and melanoma stage. PBMCs from melanoma patients (stages 0–IV), or dysplastic
nevus (DN), and from healthy donors (HDs) were analyzed for CD14 vs. HLA-DR expression, in which CD14þHLA-DRno/low cells are indicated (%). These cells
were FACS-gated and examined for expression of DC-HIL vs. CD14. Data shown are representative of each group (a). % CD14þHLA-DRno/low (b) or % DC-
HILþCD14þHLA-DRno/low cells/PBMCs (c) in each cohort is summarized (mean %±s.d.). Statistical significance for each stage was calculated by comparison
with HD. (d) % Blood DC-HILþCD14þHLA-DRno/low cells/PBMCs was assayed at indicated times post resection in nine patients with stage 0 melanoma (data for
patient M71 are in red); *Po0.001 and **Po0.01.
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melanoma, and the restoration by anti-
DC-HIL mAb of the T-cell IFN-g
response in melanoma patients consti-
tute strong bases for developing these
cells as a useful biomarker and thera-
peutic target for melanoma. Our results
should be confirmed by large, multi-
center studies.
This study was approved by The Uni-
versity of Texas Southwestern Medical
Center Institutional Review Board and
conducted according to principles of the
Declaration of Helsinki, including written
informed consent from all subjects.
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TO THE EDITOR
There is a lack of definitive epidemiolo-
gic information on patients who suffer
from hidradenitis suppurativa (HS), as
well as poor understanding of the etiol-
ogy of this process. It is essential to
gather more accurate information regard-
ing HS as understanding of disease
associations may lead to improved com-
prehension of the pathology. In their
recent report, Vazques et al. (2013)
have put forth an excellent population-
based study on this disease process,
which helps to provide valuable infor-
mation on such associations. They
found that 90.3% of the patients with
HS in Olmsted County, Minnesota, were
white, but specifically note that this
racial breakdown may be a reflection
of the racial demographics of the county
itself, which is predominantly white.
The classical teaching regarding HS
has been that this process occurs more
frequently in those of African descent
(McMichael et al., 2008). However,
many of the published epidemiologic
studies are similar to this publication in
reporting a predominance of whites
among those affected. It is important to
consider that many of these studies are
drawn from the northern or western
European populations. This may again
be a reflection of the demographics of
these regions, but this message domi-
nates the available literature.
Over the last several years, we have
increasingly recognized that there is a
large population of patients in our area
who suffer from follicular disorders,
particularly HS. As such, we have per-
formed our own retrospective review of
all HS patients seen in our clinic during
an 18-month time period from 1 January
2011 to 31 May 2012.
All encounters were searched, and
there were 366 patients identified with
the clinical diagnosis of HS seen in the
Dermatology Clinic at the Henry Ford
Medical Center during this time period.
Given that overall there were 8,480
patients seen in the clinic during this
time, HS patients comprised 4.3% of the
dermatology clinic patient population.
For 6,664 of these patients, including all
366 of the patients with the diagnosis of
HS, there were data available regarding
race. In addition, the US Census Bureau
data for Wayne County, Michigan, in
2010 (http://quickfacts.census.gov/qfd/
states/26/26163lk.html, accessed 21
May 2013) indicate that the population
of Wayne County was 54.2% white and
41.8% black. For the HS patients, 54.4%
(199) were black, 25.7% (94) were
white, and the remaining 19.9% (73)
were classified as ‘‘other.’’ Looking at
the overall population of patients seen in
the Henry Ford Dermatology Clinic for
all diagnoses, 47.0% (3,131) were black,
35.8% (2,389) were white, and 17.2%
(1,144) fell into the category of ‘‘other.’’
We found that 6.4% of the black patients
as compared with 3.9% of the white
patients seen in the clinic were seen for
the diagnosis of HS (P-value ofo0.001),
using a chi-square test, SAS9.2 (SAS,
Cary, NC) (Table 1). We feel our data
support the traditional teaching that HS
is more common in those of African
descent, which is not currently substan-
tiated in the medical literature.
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Table 1. Ethnicity of HS patients versus non-HS patients for the Henry Ford
Dermatology Clinic
White Black Other P-value
All non-HS patients 2,295 (96.1%) 2,932 (93.6%) 1,071 (93.6%) o0.001
HS patients 94 (3.9%) 199 (6.4%) 73 (6.4%)
Abbreviation: HS, hidradenitis suppurativa.
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